Board Initiates Formal Strategic Review Process for TTX-MC138 and Oncology Portfolio
TransCode Therapeutics' board of directors has initiated a formal strategic process to evaluate opportunities designed to maximize the value of the company and its oncology portfolio, including lead product candidate TTX-MC138. The process will evaluate potential transactions including licensing arrangements, asset sales, development partnerships, portfolio transactions, and business combinations. The company has engaged Tungsten Advisors as exclusive strategic financial advisor in connection with the process.
Read source-backed brief